Altimmune Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone, and welcome to the session with Altimmune. We are fortunate to have Vipin Garg and Scott Harris here from the team.
Questions & Answers
Maybe first, we could just start with an overview of the company and with a particular focus on what you view as key value drivers over the next, let's call it, 12 to 24 months.
Okay. Yes. Perfect. Thank you for having us. So at Altimmune, we are developing peptide-based therapeutics for obesity and for liver diseases. Our most advanced asset is pemvidutide, which is a GLP-1 glucagon dual receptor agonist that we are developing for obesity and for NASH. And of course, we talk more about that. We also have immunotherapeutics and other peptide-based therapeutics that we're developing for hepatitis B.
For both of these programs, we're making
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |